ETP-ALL have a distinctive gene expression signature characterized by high levels of expression of myeloid markers, i.e., LYL1, LMO2, CD34, CCND2, KIT, GATA2, and CEBPA, and low levels of expression of genes related to thymocyte differentiation, such as CD1, CD4, CD8, TCF7, and LEF1 [5,6,24]. The gene discussed is LMO2; the disease is acute lymphoblastic leukemia.